Terns Pharmaceuticals, Inc.
Business
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing internally discovered small-molecule product candidates to address oncology and metabolic diseases, including obesity. Its main products include the allosteric BCR-ABL inhibitor TERN-701, the oral small-molecule GLP-1 receptor agonist TERN-601, the THR-β agonist TERN-501, and a discovery-stage TERN-800 series of GIPR modulators. Key business activities comprise discovery, preclinical and clinical development, patenting and licensing (including an exclusive option and license with Hansoh), and reliance on third-party contract manufacturers. The company conducts global clinical trials in the United States, Europe and other countries and manages sales, marketing and distribution through internal resources and third-party relationships.
Summary from filing dated 2025-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-96.21M |
| Total assets | $1.03B |
| Total liabilities | $18.55M |
| Stockholders' equity | $1.01B |
| Operating cash flow | $-82.18M |